Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 51Small Cell Lung Carcinoma 23Lung Neoplasms 10NSCLC 5Non-squamous Non-small Cell Lung Cancer 3Neoplasms 3Carcinoma 3Extensive Stage Small Cell Lung Cancer 2Brain Neoplasms 2Adenocarcinoma of Lung 2Squamous Non-small Cell Lung Cancer 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1SCLC 1Non-squamous Non-small-cell Lung Cancer 1Non-squamous Cell Non-Small Cell Lung Cancer 1Non-Squamous Non Small Cell Lung Cancer 1Non Small Cell Lung Cancer Recurrent 1Neoplasm, Residual 1Neoplasm Metastasis 1Locally Advanced Non-small Cell Lung Cancer 1Limited Stage Small Cell Lung Cancer 1IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy 1Extensive Small Cell Lung Cancer 1Aumolertinib 1Advanced Non-small Cell Lung Cancer 1

Interventions

Immunotherapy 2anlotinib 1Radiotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Non-small Cell Lung Cancer × anlotinib × Thoracic × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡